Abstract
Background Given the exposure risk of comorbidities in Mexican society, the new pandemic involves the highest risk for the population in the history.
Objective This article presents an analysis of the COVID-19 risk from Mexico’s regions.
Method The study period runs from April 12 to June 29, 2020 (220,667 patients). The method has a nature applied and according to its level of deepening in the object of study it is framed in a descriptive and explanatory analysis type. The data used here has a quantitative and semi-quantitative characteristic because they are the result of a questionnaire instrument made up of 34 fields and the virus test. The instrument is of a deliberate type. According to the manipulation of the variables, this research is a secondary type of practices, and it has a factual inference from an inductive method because it is emphasizing the concomitant variations for each region of the country.
Results Region 1 and Region 4 have a higher percentage of hospitalized patients, while Region 2 has a minimum of them. The average age of non-hospitalized patients is around 40 years old, while the hospitalized patients’ age it is close to 55 years. The most sensitive comorbidities in hospitalized patients are three principal: obesity, diabetes mellitus and hypertension. The patients whose needed the mechanical respirator were in ranged from 7.45% to 10.79%.
Conclusions There is a higher risk of lose their lives in the Region 1 and Region 4 territories than in the Region 2, this information was dictated by the statistical analysis..
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Exemptiom.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos